PURPOSE: For some women, adjuvant chemotherapy for nonmetastatic breast cancer decreases recurrences and increases survival; however, patient-physician decisions regarding chemotherapy receipt can be influenced by medical and nonmedical factors. PATIENTS AND METHODS: We used a prospective cohort design and multivariate modeling to investigate factors related to noninitiation of chemotherapy among women with newly diagnosed breast cancer recruited from three US sites. We interviewed patients at baseline and during treatment on sociodemographic, tumor, and treatment decision-making factors. Patients were categorized according to National Comprehensive Cancer Network guidelines as those for whom chemotherapy was definitely indicated, clinically discretionary, or discretionary based on age greater than 70 years. RESULTS: Of 1,145 patients recruited, chemotherapy was clinically indicated for 392 patients, clinically discretionary for 459 patients, discretionary because of age for 169 patients, and not indicated for 93 patients; data were insufficient for 32 patients. Chemotherapy rates were 90% for those in whom chemotherapy was clinically indicated, 36% for those in whom it was discretionary because of clinical factors, and 19% for those in whom it was discretionary based on age greater than 70 years. Nonreceipt of chemotherapy was associated with older age, more negative beliefs about treatment efficacy, less positive beliefs about chemotherapy, and more concern about adverse effects. In the two discretionary groups, clinical predictors of worse outcome (greater tumor size, positive nodes, worse grade, and estrogen receptor- and progesterone receptor-negative status) were associated with increased chemotherapy initiation. CONCLUSION: Utilization of adjuvant chemotherapy was most common among patients who, based on clinical criteria, would most likely benefit from it, patients with more positive than negative beliefs regarding treatment efficacy, and patients with few concerns about adverse effects.
PURPOSE: For some women, adjuvant chemotherapy for nonmetastatic breast cancer decreases recurrences and increases survival; however, patient-physician decisions regarding chemotherapy receipt can be influenced by medical and nonmedical factors. PATIENTS AND METHODS: We used a prospective cohort design and multivariate modeling to investigate factors related to noninitiation of chemotherapy among women with newly diagnosed breast cancer recruited from three US sites. We interviewed patients at baseline and during treatment on sociodemographic, tumor, and treatment decision-making factors. Patients were categorized according to National Comprehensive Cancer Network guidelines as those for whom chemotherapy was definitely indicated, clinically discretionary, or discretionary based on age greater than 70 years. RESULTS: Of 1,145 patients recruited, chemotherapy was clinically indicated for 392 patients, clinically discretionary for 459 patients, discretionary because of age for 169 patients, and not indicated for 93 patients; data were insufficient for 32 patients. Chemotherapy rates were 90% for those in whom chemotherapy was clinically indicated, 36% for those in whom it was discretionary because of clinical factors, and 19% for those in whom it was discretionary based on age greater than 70 years. Nonreceipt of chemotherapy was associated with older age, more negative beliefs about treatment efficacy, less positive beliefs about chemotherapy, and more concern about adverse effects. In the two discretionary groups, clinical predictors of worse outcome (greater tumor size, positive nodes, worse grade, and estrogen receptor- and progesterone receptor-negative status) were associated with increased chemotherapy initiation. CONCLUSION: Utilization of adjuvant chemotherapy was most common among patients who, based on clinical criteria, would most likely benefit from it, patients with more positive than negative beliefs regarding treatment efficacy, and patients with few concerns about adverse effects.
Authors: Bijal A Balasubramanian; Sampada K Gandhi; Kitaw Demissie; David A August; Betsy Kohler; Omowunmi Y Osinubi; George G Rhoads Journal: Cancer Control Date: 2007-01 Impact factor: 3.302
Authors: Vlatka M Duric; Phyllis N Butow; Louise Sharpe; Frances Boyle; Jane Beith; Nicholas R C Wilcken; Stephane Heritier; Alan S Coates; R John Simes; Martin R Stockler Journal: Psychooncology Date: 2007-01 Impact factor: 3.894
Authors: Hyman B Muss; Donald A Berry; Constance Cirrincione; Daniel R Budman; I Craig Henderson; Marc L Citron; Larry Norton; Eric P Winer; Clifford A Hudis Journal: J Clin Oncol Date: 2007-08-20 Impact factor: 44.544
Authors: Heather Greenlee; Alfred I Neugut; Laura Falci; Grace Clarke Hillyer; Donna Buono; Jeanne S Mandelblatt; Janise M Roh; Isaac J Ergas; Marilyn L Kwan; Marion Lee; Wei Yann Tsai; Zaixing Shi; Lois Lamerato; Lawrence H Kushi; Dawn L Hershman Journal: JAMA Oncol Date: 2016-09-01 Impact factor: 31.777
Authors: Alfred I Neugut; Grace Clarke Hillyer; Lawrence H Kushi; Lois Lamerato; Nicole Leoce; Christine B Ambrosone; Dana H Bovbjerg; Jeanne S Mandelblatt; Dawn L Hershman Journal: Breast Cancer Date: 2014-06-06 Impact factor: 4.239
Authors: Joseph M Unger; Dawn L Hershman; Diane Martin; Ruth B Etzioni; William E Barlow; Michael LeBlanc; Scott R Ramsey Journal: J Natl Cancer Inst Date: 2014-12-24 Impact factor: 13.506
Authors: Christine Y Lu; Fang Zhang; Anita K Wagner; Larissa Nekhlyudov; Craig C Earle; Matthew Callahan; Robert LeCates; Xin Xu; Dennis Ross-Degnan; J Frank Wharam Journal: Breast Cancer Res Treat Date: 2018-05-12 Impact factor: 4.872
Authors: Gery P Guy; Joseph Lipscomb; Theresa W Gillespie; Michael Goodman; Lisa C Richardson; Kevin C Ward Journal: Health Serv Res Date: 2014-12-10 Impact factor: 3.402
Authors: Abigail Silva; Garth H Rauscher; Kent Hoskins; Ruta Rao; Carol Estwing Ferrans Journal: Breast Cancer Res Treat Date: 2013-11-22 Impact factor: 4.872
Authors: Rachel C Shelton; Grace Clarke Hillyer; Dawn L Hershman; Nicole Leoce; Dana H Bovbjerg; Jeanne S Mandelblatt; Lawrence H Kushi; Lois Lamerato; S David Nathanson; Christine B Ambrosone; Alfred I Neugut Journal: Breast Cancer Res Treat Date: 2012-12-22 Impact factor: 4.872
Authors: Alfred I Neugut; Grace Clarke Hillyer; Lawrence H Kushi; Lois Lamerato; Donna L Buono; S David Nathanson; Dana H Bovbjerg; Jeanne S Mandelblatt; Wei-Yann Tsai; Judith S Jacobson; Dawn L Hershman Journal: Breast Cancer Res Treat Date: 2016-06-10 Impact factor: 4.872
Authors: Lukas Schwentner; Reyn Van Ewijk; Thorsten Kühn; Felix Flock; Riccardo Felberbaum; Maria Blettner; Rolf Kreienberg; Wolfgang Janni; Achim Wöckel; Susanne Singer Journal: Support Care Cancer Date: 2016-01-27 Impact factor: 3.603
Authors: Lorraine T Dean; Shadiya L Moss; Anne Marie McCarthy; Katrina Armstrong Journal: Cancer Epidemiol Biomarkers Prev Date: 2017-09-29 Impact factor: 4.254